Patents Assigned to Genentech
  • Methods for identifying safe and functional humanized antibodies
    Patent number: 9221900
    Abstract: The present invention is related to safe and functional antibodies for the therapeutic and diagnostic use in the treatment of an amyloidosis, a group of disorders and abnormalities associated with amyloid protein, such as Alzheimer's disease.
    Type: Grant
    Filed: July 29, 2011
    Date of Patent: December 29, 2015
    Assignees: AC IMMUNE S.A., GENENTECH, INC.
    Inventors: Andrea Pfeifer, Andreas Muhs, Oskar Adolfsson, Ryan J. Watts
  • ANTI-WALL TEICHOIC ANTIBODIES AND CONJUGATES
    Publication number: 20150366985
    Abstract: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.
    Type: Application
    Filed: May 22, 2014
    Publication date: December 24, 2015
    Applicant: GENENTECH, INC.
    Inventors: Eric J. Brown, John Flygare, Wouter Hazenbos, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen
  • KLOTHO BETA
    Publication number: 20150368358
    Abstract: The invention concerns uses of anti-KL? agents, and detection of KL? and/or FGF19 and/or FGFR4.
    Type: Application
    Filed: March 26, 2015
    Publication date: December 24, 2015
    Applicant: GENENTECH, INC.
    Inventor: Luc Desnoyers
  • DIAZACARBAZOLES AND METHODS OF USE
    Publication number: 20150368244
    Abstract: The invention relates to 1,5-diazacarbazole compounds of Formula (I), (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g) and (I-h) which are useful as kinase inhibitors, more specifically useful as checkpoint kinase 1 (chk1) inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.
    Type: Application
    Filed: December 20, 2013
    Publication date: December 24, 2015
    Applicant: Genentech, Inc.
    Inventors: Hazel Joan Dyke, Emanuela Gancia, Lewis J. Gazzard, Simon Charles Goodacre, Joseph P. Lyssikatos, Calum MacLeod, Karen Williams, Huifen Chen
  • Methods of use of diazacarbazoles for treating cancer
    Patent number: 9216980
    Abstract: Methods of use of compounds of formula (I) for treating cancer: wherein X, Y, X, R3, R5 and R6 are as defined herein.
    Type: Grant
    Filed: April 17, 2014
    Date of Patent: December 22, 2015
    Assignee: Genentech, Inc.
    Inventors: Huifen Chen, Hazel Joan Dyke, Charles Ellwood, Emanuela Gancia, Lewis J. Gazzard, Simon Goodacre, Samuel Kintz, Joseph Lyssikatos, Calum MacLeod, Karen Williams
  • Benzyl sulfonamide derivatives as RORc modulators
    Patent number: 9216988
    Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, A, X1, X2, X3, X4, R1, R2, R3a, R3b, R4a and R4b are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.
    Type: Grant
    Filed: December 18, 2012
    Date of Patent: December 22, 2015
    Assignee: Genentech, Inc.
    Inventors: Benjamin Fauber, Olivier Rene
  • LIQUID CULTURING OF EPITHELIAL STEM CELLS
    Publication number: 20150361392
    Abstract: Provided herein is a method of culturing epithelial stem cells and tissue fragments comprising epithelial stem cells in liquid cultures.
    Type: Application
    Filed: August 25, 2015
    Publication date: December 17, 2015
    Applicant: GENENTECH, INC.
    Inventor: Brian Biehs
  • METHODS OF MODULATING DLK STABILITY
    Publication number: 20150361184
    Abstract: The invention provides for methods of decreasing dual leucine zipper kinase (DLK) stability in a neuron, or decreasing or inhibiting the phosphorylation of certain amino acid residues of DLK, comprising administering to a neuron, or portion thereof, an agent which decreases or inhibits the phosphorylation of DLK and decreases the stability of DLK as well as methods for inhibiting or preventing neuronal degeneration in a patient by administering to a patient an agent which inhibits phosphorylation of dual leucine zipper kinase (DLK).
    Type: Application
    Filed: August 28, 2015
    Publication date: December 17, 2015
    Applicant: GENENTECH, INC.
    Inventors: Daisy BUSTOS, Sarah HUNTWORK-RODRIGUEZ, Donald KIRKPATRICK, Joseph Wesley LEWCOCK, Arundhati Sengupta GHOSH
  • Pyrazole aminopyrimidine derivatives as LRRK2 modulators
    Patent number: 9212173
    Abstract: Pyrazole compounds that are modulators of LRRK2, methods of making the compounds, and methods for using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.
    Type: Grant
    Filed: November 3, 2014
    Date of Patent: December 15, 2015
    Assignee: Genentech, Inc.
    Inventors: Charles Baker-Glenn, Daniel Jon Burdick, Bryan K. Chan, Mark Chambers, Huifen Chen, Anthony Estrada, Zachary Kevin Sweeney
  • Bicyclic pyrazole LRRK2 small molecule inhibitors
    Patent number: 9212186
    Abstract: Compounds of formula I: or pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3 and A are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.
    Type: Grant
    Filed: November 3, 2014
    Date of Patent: December 15, 2015
    Assignee: Genentech, Inc.
    Inventors: Charles Baker-Glenn, Bryan K. Chan, Jennafer Dotson, Anthony Estrada, Timothy Heffron, Joseph Lyssikatos, Zachary Sweeney
  • 5-anilinoimidazopyridines and methods of use
    Patent number: 9206174
    Abstract: The invention relates to a method of inhibiting abnormal cell growth or treating a hyperproliferative disorder in a mammal comprising administering to said mammal a therapeutically effective amount of an imidazopyridine of formula I with anti-hyperproliferative activity.
    Type: Grant
    Filed: February 5, 2013
    Date of Patent: December 8, 2015
    Assignee: Genentech, Inc.
    Inventor: Robert Heald
  • Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof
    Patent number: 9206175
    Abstract: The invention provides novel compounds having the general formula: wherein X1 is N or N+O?, and one of X2, X3 and X4 is N or N+—O? and the remainder of X2, X3 and X4 is C. R2, R3, R4, R5, R6. A, B and Y are as described herein. Additionally compositions compounds of Formula I and methods of use are further described herein.
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: December 8, 2015
    Assignee: GENENTECH, INC.
    Inventors: Joseph P. Lyssikatos, Lewis J. Gazzard, Emily Hanan, Samuel S. Kintz, Hans Edward Purkey
  • USP30 INHIBITORS AND METHODS OF USE
    Publication number: 20150344888
    Abstract: Inhibitors of USP30 and methods of using inhibitors of USP30 are provided. In some embodiments, methods of treating conditions involving mitochondrial defects are provided.
    Type: Application
    Filed: March 16, 2015
    Publication date: December 3, 2015
    Applicant: GENENTECH, INC.
    Inventors: Yingnan Zhang, Baris Bingol, Jacob Corn
  • Refolding of recombinant proteins
    Patent number: 9200030
    Abstract: Processes are provided for recovering and purifying refolded recombinant proteins produced in heterologous host cells, which includes the step of refolding the protein in a high pH buffer.
    Type: Grant
    Filed: November 2, 2012
    Date of Patent: December 1, 2015
    Assignee: Genentech, Inc.
    Inventors: Shelly Pizarro, Ailen Sanchez, Charles H. Schmelzer
  • Benzoxazepin PI3K inhibitor compounds and methods of use
    Patent number: 9198918
    Abstract: Benzoxazepin compounds of Formula I, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z1 is CR1 or N; Z2 is CR2 or N; Z3 is CR3 or N; Z4 is CR4 or N; and B is a pyrazolyl, imidazolyl, or triazolyl ring fused to the benzoxepin ring, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: December 1, 2015
    Assignee: GENENTECH, INC.
    Inventors: Nicole Blaquiere, Steven Do, Danette Dudley, Adrian Folkes, Robert Heald, Timothy Heffron, Mark Jones, Aleksandr Kolesnikov, Chudi Ndubaku, Alan G. Olivero, Stephen Price, Steven Staben, Lan Wang
  • Anti-LRP5 antibodies and methods of use
    Patent number: 9200072
    Abstract: The invention provides anti-LRP5 antibodies and methods of making and using the same.
    Type: Grant
    Filed: January 18, 2013
    Date of Patent: December 1, 2015
    Assignee: GENENTECH INC.
    Inventors: Yan Wu, Weilan Ye, Jeremy Bryant Burton, Cecilia Chiu
  • Methods of treating cancer using Notch1 and Notch3 antagonists
    Patent number: 9200071
    Abstract: The present invention relates to methods of treating cancer in general, and leukemia in particular, using Notch1 and Notch3 antagonists singly or in combination. Compositions and methods for the treatment and diagnosis of Notch-associated cancers are also provided.
    Type: Grant
    Filed: September 29, 2010
    Date of Patent: December 1, 2015
    Assignee: Genentech, Inc.
    Inventor: Christian W. Siebel
  • METHODS OF TREATING PR-POSITIVE, LUMINAL A BREAST CANCER WITH PI3K INHIBITOR, PICTILISIB
    Publication number: 20150335650
    Abstract: Methods and compositions are provided for treating breast cancer in patients with a PI3K inhibitor, GDC-0941 in combination with an endocrine therapy agent.
    Type: Application
    Filed: May 20, 2015
    Publication date: November 26, 2015
    Applicant: Genentech, Inc.
    Inventors: Mika K. Derynck, Lori Friedman, Steven Brian Gendreau, Sandra Milan
  • METHODS FOR INACTIVATION OF VIRUSES AND BACTERIA IN CELL CULTURE MEDIA
    Publication number: 20150337269
    Abstract: The invention provides for methods of viral inactivation using high temperature short time (HTST) treatment and adjustment of various parameters such that generation of precipitate and depositions of precipitate are reduced and/or minimized.
    Type: Application
    Filed: December 19, 2014
    Publication date: November 26, 2015
    Applicant: GENENTECH, INC.
    Inventors: MASARU KEN SHIRATORI, ROBERT DAVID KISS, HARDAYAL PRASHAD, RAQUEL IVERSON, JUSTIN BOURRET, MICHAEL KIM, SALIM CHARANIYA
  • 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20150336962
    Abstract: Compounds of Formula (00A) and methods of use as Janus kinase inhibitors are described herein.
    Type: Application
    Filed: May 22, 2015
    Publication date: November 26, 2015
    Applicant: Genentech, Inc.
    Inventors: Mark Edward Zak, Nicholas Charles Ray, Simon Charles Goodacre, Rohan Mendonca, Terry Kellar, Yun-Xing Cheng, Wei Li, Po-Wai Yuen